Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB039A in advanced solid tumors
NCT06345482Phase 2Active, not recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MHB039A in solid tumor (advanced stage), sponsored by Minghui Pharmaceutical, Inc.. Started Apr 2024; status: active, not recruiting.
02
Drugs
MHB039A
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06345482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345482.